Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.

ARDS COVID19-ARDS DEspR neutrophil subset secondary tissue injury

Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
13 Sep 2021
Historique:
pubmed: 22 9 2021
medline: 22 9 2021
entrez: 21 9 2021
Statut: epublish

Résumé

Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to severe COVID19. This 'innocent bystander' tissue injury arises in dysregulated hyperinflammatory states from neutrophil functions and neutrophil extracellular traps (NETs) intended to kill pathogens, but injure cells instead, causing MOF. Insufficiency of prior therapeutic approaches suggest need to identify dysregulated neutrophil-subset(s) and induce subset-specific apoptosis critical for neutrophil function-shutdown and clearance. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/signal peptide receptor, DEspR, are apoptosis-resistant just like DEspR+ cancer cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID19-ARDS. Here, we report correlation of circulating DEspR+CD11b+ activated neutrophils (DESpR+actNs) and NETosing-neutrophils with severity in ARDS and in COVID19-ARDS, increased DEspR+ neutrophils and monocytes in post-mortem ARDS-patient lung sections, and neutrophil DEspR/ET1 receptor/ligand autocrine loops in severe COVID19. Unlike DEspR[-] neutrophils, ARDS patient DEspR+actNs exhibit apoptosis-resistance, which decreased upon

Identifiants

pubmed: 34545358
doi: 10.21203/rs.3.rs-846250/v1
pmc: PMC8452107
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NHLBI NIH HHS
ID : U54 HL119145
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001430
Pays : United States

Auteurs

Victoria L M Herrera (VLM)

Boston University School of Medicine.

Allan J Walkey (AJ)

Boston University School of Medicine.

Mai Q Nguyen (MQ)

Boston University School of Medicine.

Christopher M Gromisch (CM)

Boston University School of Medicine.

Julie Z Mosaddhegi (JZ)

Boston University School of Medicine.

Matthew S Gromisch (MS)

Boston University School of Medicine.

Bakr Jundi (B)

Brigham and Women's Hospital, Harvard Medical School.

Soeren Lukassen (S)

Berlin Institute of Health and Charité - Universitätsmedizin Berlin, Universität Berlin, Humboldt-Universität zu Berlin.

Saskia Carstensen (S)

Fraunhofer Institute for Toxicology and Experimental Medicine.

Ridiane Denis (R)

Boston University School of Medicine.

Anna C Belkina (AC)

Boston University School of Medicine.

Rebecca M Baron (RM)

Brigham and Women's Hospital, Harvard Medical School.

Mayra Pinilla-Vera (M)

Brigham and Women's Hospital, Harvard Medical School.

Meike Muller (M)

Fraunhofer Institute for Toxicology and Experimental Medicine.

W Taylor Kimberly (WT)

Massachusetts General Hospital, Harvard Medical School.

Joshua N Goldstein (JN)

Massachusetts General Hospital, Harvard Medical School.

Irina Lehmann (I)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH).

Angela R Shih (AR)

Massachusetts General Hospital, Harvard Medical School.

Roland Ells (R)

Berlin Institute of Health and Charité - Universitätsmedizin Berlin, Universität Berlin, Humboldt-Universität zu Berlin.

Bruce D Levy (BD)

Brigham and Women's Hospital, Harvard Medical School.

Nelson Rulz-Opazo (N)

Boston University School of Medicine.

Classifications MeSH